NCT03616301View on ClinicalTrials.gov

Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 28, 2018

Primary Completion Date

August 13, 2018

Study Completion Date

August 13, 2018

Conditions
Bioequivalence
Interventions
DRUG

Clavamox

Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus

DRUG

Augmentin®

Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia

Trial Locations (1)

150010

"State Autonomous Healthcare Facility of the Yaroslavl Region Clinical Hospital No. 2", Yaroslavl

All Listed Sponsors
collaborator

ClinPharmInvest, LLC

OTHER

lead

Pharmtechnology LLC

INDUSTRY

NCT03616301 - Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions | Biotech Hunter | Biotech Hunter